Navigation Links
Rotavirus vaccine developed in India demonstrates strong efficacy
Date:5/14/2013

the social innovation partnership and ensuring the highest standards for the vaccine.

The randomized, double-blind, placebo-controlled Phase III clinical trial enrolled 6,799 infants in India (aged six to seven weeks at the time of enrolment) at three sitesthe Centre for Health Research and Development, Society for Applied Studies (SAS) in New Delhi; Shirdi Sai Baba Rural Hospital, KEM Hospital Research Centre in Vadu, Pune; and Christian Medical College (CMC) in Vellore. The Clinical Operations Management Unit headed by Dr Nita Bhandari at SAS oversaw the day-to-day coordination and logistical complexities of this multi-site study and played a pivotal role in the conduct of this trial. The Principal Investigators were Dr Temsunaro Rongsen-Chandola at SAS, Dr Ashish Bavdekar at KEM, and Dr Gagandeep Kang at CMC.

The Data Safety Monitoring Board (DSMB), an independent group of experts established to protect the participating infants' rights and needs during the Phase III trial, determined that the trial met the highest standards for ethics and patient care and complied with international standards for good clinical practices.

Bharat Biotech previously announced a price of US$ 1.00/dose (or approximately INR 54/dose) for ROTAVAC and will soon file for registration of the vaccine in India. If licensed by the Drugs Controller General of India (DCGI), the vaccine will be a more affordable alternative to the rotavirus vaccines already on the market.

"With its low price and strong efficacy, ROTAVAC has the potential to significantly reduce the incidence of severe diarrhoea due to rotavirus among children in India," said Dr M.K. Bhan, Advisor to the Indian Academy of Pediatrics and former DBT Secretary.

The vaccine efficacy compares favourably with the efficacy of the currently licensed rotavirus vaccines in low-resource countries. The study results showed clear evidence of protection across different rotavirus strains and
'/>"/>

Contact: Allison Clifford
aclifford@path.org
202-669-7238
PATH
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Queens scientists seek vaccine for Pseudomonas infection
2. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
3. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
4. SFU HIV/AIDS vaccine research gets financial boost
5. Researchers identify Achilles heel of dengue virus, target for future vaccines
6. AAPS National Biotechnology Conference to highlight innovative vaccines
7. Army study: DNA vaccine and duck eggs protect against hantavirus disease
8. Sensitive test helps improve vaccine safety
9. Overweight? Theres a vaccine for that
10. Vaccine and antibiotics stabilized so refrigeration is not needed -- NIH study
11. Scripps Research Institute wins $77 million to develop AIDS vaccine center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
(Date:6/25/2015)... LAKE CITY , June 25, 2015  Imagine ... first steps toward a healthier, happier life. That,s exactly ... is designed to do. The cutting-edge, portable health program ... offers real-life solutions to help improve your lifestyle and ... Association awards dinner and gala Wednesday night, USANA,s THA ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... 2010 Tel Aviv University President Professor, ... together a myriad of seemingly unrelated chemical reactions creating a ... Chemistry on April 18 , contributes to our understanding ... motion of molecules or other particles within that medium, determining ...
... increasingly being produced using container nursery systems rather ... field production techniques, successful container production requires a ... sequentially transferred to larger containers, a practice known ... arise when trees are planted either too deep ...
... Combining telephone counseling calls with a daily written diet ... vegetables consumption, according to research published in Preventive ... health care for many reasons, including lack of time, ... Ph.D., research professor in the department of family medicine ...
Cached Biology News:Tel Aviv University President Co-authors Important Paper Unraveling the Effect of Spatial Organization on Intracellular Chemistry 2Tel Aviv University President Co-authors Important Paper Unraveling the Effect of Spatial Organization on Intracellular Chemistry 3Planting depth affects popular landscape tree 2Telephone counseling increases daily servings of fruit, vegetables, U-M study says 2
(Date:7/27/2015)... /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or ... for the treatment of cancer, today provides the following ... closed a $1,000,000 unit offering private placement.  This financing ... the Company at a price of $0.06 per unit.  ... one common share purchase warrant.  Each whole warrant is ...
(Date:7/27/2015)... ... ... Production of high tenacity filament yarn of viscose rayon (excluding sewing thread) demonstrated ... surpassed the EUR 106 million mark (in value terms) in 2013, while it stood ... while Italy is a key consumer. , The high tenacity filament yarn of ...
(Date:7/27/2015)... , July 27, 2015   Inocucor Technologies ... sustainable biological accelerators for farmers, has received a ... Trademark Office for its patent application to protect ... plant growth and enhance yields on farms and ... to Inocucor,s live IN-M1 microbial consortium and its ...
(Date:7/27/2015)... ... 27, 2015 , ... BlueInGreen® announced the addition of EnviroSales ... the world’s most efficient gas dissolution technology to all of Florida, excluding the ... industrial and municipal markets. With offices located in Sarasota, Sebring and Melbourne Beach, ...
Breaking Biology Technology:Quest PharmaTech Closes $1,000,000 Private Placement 2High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3BlueInGreen Brings Water Treatment Technology to Florida 2
... or the "Company") (Amex: SNT ) today reported,financial results ... loss for the three month period ended December 31, 2007 ... loss of $1.1 million, or,$0.07 per share, for the three ... was primarily the result of a decrease in revenue and,an ...
... and Medical Affairs, NEW YORK, Feb. 15 ... Lou DeBergalis has joined the,Company as Vice President, Quality ... the Company later this month in the role of,Vice ... will,report directly to Michael S. Weiss, Chief Executive Officer., ...
... SAN DIEGO, Feb. 15 Cadence Pharmaceuticals,Inc. (Nasdaq: ... in-licensing,developing and commercializing proprietary product candidates principally,for use ... has received,commitments from selected investors to purchase up ... purchase price of $5.34 per share pursuant to,an ...
Cached Biology Technology:Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 2Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 4Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 5Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 6Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 7Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 8Keryx Biopharmaceuticals Announces Additions to Management Team 2Keryx Biopharmaceuticals Announces Additions to Management Team 3Keryx Biopharmaceuticals Announces Additions to Management Team 4Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering 2
CREB-2 (H-290)...
... Rabbit polyclonal to Parathyroid Hormone Receptor ... tested applications). Antigen: ... extracellular amino acids 99-116 of Human ... Entrez Gene ID: 5746 ...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
NAP-2 (5C7)...
Biology Products: